Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NASDAQ:HOOK NASDAQ:INAB NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$16.12+0.8%$16.99$3.66▼$42.12$35.46M1.5310,719 shs411 shsHOOKHOOKIPA Pharma$1.18-0.8%$1.09$0.81▼$1.77$14.55M0.8411,180 shs12,603 shsINABIN8bio$1.58-2.8%$1.59$1.17▼$5.61$15.50M0.0871,779 shs29,869 shsVIVSVivoSim Labs$1.41-0.6%$1.69$1.25▼$5.30$3.68M1.411.20 million shs6,063 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics-2.27%+21.99%+7.70%-18.62%+158.19%HOOKHOOKIPA Pharma+0.42%+3.48%+3.48%+13.33%-7.03%INABIN8bio+8.00%+5.88%+12.50%-17.35%-67.63%VIVSVivoSim Labs-1.39%-4.70%-15.98%-39.57%+141,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$16.12+0.8%$16.99$3.66▼$42.12$35.46M1.5310,719 shs411 shsHOOKHOOKIPA Pharma$1.18-0.8%$1.09$0.81▼$1.77$14.55M0.8411,180 shs12,603 shsINABIN8bio$1.58-2.8%$1.59$1.17▼$5.61$15.50M0.0871,779 shs29,869 shsVIVSVivoSim Labs$1.41-0.6%$1.69$1.25▼$5.30$3.68M1.411.20 million shs6,063 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics-2.27%+21.99%+7.70%-18.62%+158.19%HOOKHOOKIPA Pharma+0.42%+3.48%+3.48%+13.33%-7.03%INABIN8bio+8.00%+5.88%+12.50%-17.35%-67.63%VIVSVivoSim Labs-1.39%-4.70%-15.98%-39.57%+141,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 1.00SellN/AN/AHOOKHOOKIPA Pharma 0.00N/AN/AN/AINABIN8bio 2.00Hold$4.00153.97% UpsideVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest VIVS, INAB, APLM, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$8.50M4.17N/AN/A($2.89) per share-5.58HOOKHOOKIPA Pharma$9.35M1.56N/AN/A$4.25 per share0.28INABIN8bioN/AN/AN/AN/A$2.82 per shareN/AVIVSVivoSim Labs$140K26.31N/AN/A$5.54 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/AN/AHOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%5/7/2026 (Estimated)INABIN8bio-$19.44M-$4.45N/AN/AN/AN/A-111.30%-88.07%5/6/2026 (Estimated)VIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/ALatest VIVS, INAB, APLM, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026INABIN8bio-$0.59N/AN/AN/AN/AN/A3/12/2026Q4 2025INABIN8bio-$0.18-$0.26-$0.08-$0.26N/AN/A2/11/2026Q3 2025VIVSVivoSim LabsN/A-$1.03N/A-$1.03N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A0.960.96HOOKHOOKIPA PharmaN/A3.613.61INABIN8bioN/A8.828.82VIVSVivoSim LabsN/A2.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%HOOKHOOKIPA Pharma63.88%INABIN8bio92.05%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/AHOOKHOOKIPA Pharma3.30%INABIN8bio14.50%VIVSVivoSim Labs2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics452.20 millionN/ANot OptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableINABIN8bio209.85 million8.42 millionNot OptionableVIVSVivoSim Labs202.61 million2.54 millionN/AVIVS, INAB, APLM, and HOOK HeadlinesRecent News About These CompaniesVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human ...April 30, 2026 | bakersfield.comBVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | financialpost.comFVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Real TimeApril 7, 2026 | nasdaq.comVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | financialpost.comFVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | globenewswire.comVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | financialpost.comFVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | globenewswire.comVivoSim Labs Stock Price HistoryMarch 4, 2026 | investing.comVivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 4, 2026 | finanznachrichten.deVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | financialpost.comFVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | globenewswire.comVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | financialpost.comFVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Analyst ResearchFebruary 4, 2026 | nasdaq.comWhy is VIVS stock up 79% today?January 30, 2026 | msn.comVivoSim Labs Expands Commercial Presence in Asia-Pacific with Distribution Agreements in Korea and China for NAMKind™ Toxicology ServicesJanuary 29, 2026 | quiverquant.comQVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | financialpost.comFVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | globenewswire.comVivoSim Labs Inc.January 14, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Rust to Riches: The Great Resource Realignment By Jeffrey Neal Johnson | April 9, 2026VIVS, INAB, APLM, and HOOK Company DescriptionsApollomics NASDAQ:APLM$16.12 +0.12 (+0.75%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.HOOKIPA Pharma NASDAQ:HOOK$1.18 -0.01 (-0.84%) As of 10:26 AM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.IN8bio NASDAQ:INAB$1.58 -0.05 (-2.78%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. VivoSim Labs NASDAQ:VIVS$1.41 -0.01 (-0.63%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
